Skip to main content

Table 1 Summary results of three NCI-MATCH sub-studies [12,13,14]

From: Umbrella and basket trials in oncology: ethical challenges

Sub-study

Pts enrolled N

Pts evaluable for response N

PR (%)

SD (%)

PD (%)

PFS6 rate (%)

Pts evaluable for toxicity N

AEs (%)

Grade 3/4 AEs (%)

Comments

Arm W: Pts with FGFR1–3 mutation or translocation receive FGFR Inhibitor AZD4547 [12]

52

41

5

51

44

17

49

80

49

Failed to meet its primary endpoint

Arm Q: Pts with HER2 amplification receive trastuzumab emtansine [13]

N/R

37

8.1

43

N/R

24.8

N/R

N/R

N/R

Failed to meet its primary endpoint

Arm I: Pts with PIK3CA mutation without RAS mutation or PTEN loss receive taselisib [14]

65

N/R

0

N/R

N/R

27

N/R

N/R

N/R

Failed to meet its primary endpoint; Co-occurring mutations were detected in 67% of tumors; 11% of pts. discontinued taselisib because of toxicity

  1. AEs Adverse events, N/R Not reported, OR Objective response, PD Progressive disease, PFS6 Progression-free survival at 6 months of treatment, PR Partial response, Pts Patients, SD Stable disease